Announcement

Collapse
No announcement yet.

Cidrap: ICEID COVERAGE Experts air H1N1 lessons, other disease challenges

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • Cidrap: ICEID COVERAGE Experts air H1N1 lessons, other disease challenges

    Lisa Schnirring * Staff Writer

    Jul 12, 2010 ? ATLANTA (CIDRAP News) ? The vital role of preparedness, from diagnostic testing to stockpiling of antiviral medications, was one of the most important lessons from assessments of the world's response to the H1N1 influenza pandemic, the World Health Organization's (WHO's) top flu expert told an international infectious diseases conference yesterday.

    Keiji Fukuda, MD, special influenza adviser to WHO Director-General Margaret Chan, said the revised International Health Regulations (IHRs), adopted by the World Health Assembly after the 2004 reemergence of the H5N1 avian influenza virus, pushed countries to be more open when the first novel H1N1 cases emerged last spring in California and Mexico.

    "It set a critical precedent and set a tone that was important for the whole global response," Fukuda said in a keynote address on lessons of the H1N1 pandemic at the opening session of the International Conference on Emerging Infectious Diseases (ICEID).

    Thomas Frieden, MD, director of the US Centers for Disease Control and Prevention (CDC), and Anthony Fauci, MD, director of the National Institute of Allergy and Infectious Diseases (NIAID), also gave keynote presentations touching on a wide range of infectious disease issues.

    Fukuda said it's clear that preparedness activities should include groups outside healthcare, such as transportation and private sector organizations. "It's broader than just health. We can't strictly think of these issues as diseases, we have to think of them as social issues," he said, referring to border and trade issues that arose soon after the pandemic virus emerged.

    The IHRs were designed to balance health issues with other global concerns such as trade and business, he said, adding that the regulations represent a paradigm shift toward a more active approach of quickly identifying and containing diseases rather than just trying to keep them from crossing borders.

    Preparation for future disease threats should keep moving forward, Fukuda said. "We need to make sure science is the basis for policy decisions," he said. "It will never be the only thing on the table, but it has to be on the table.

    Another lesson health officials learned from the H1N1 pandemic is that despite political will and strong private-sector support, efforts were inadequate for rapidly moving pandemic vaccine to low- and middle-income countries, Fukuda said. Early in the pandemic, 99 countries had asked for vaccine, but so far only 61 countries have received 45 million doses, with 22 million more slated for delivery by the end of July, he said.

    During the H1N1 response, public health officials learned that they will need to shift their communication strategies to keep up with social networking sites and other forms of citizen journalism such as blogging, Fukuda said, adding that information no longer comes top-down from experts and filtered by the major news media.

    The new media have the capacity to shape global perceptions and understanding and have the advantages of being innovative, direct, interactive, and personal, he said. However, he said that without the voice of authority and a filter, the marketplace decides what's good or bad, which can lead to misinformation, confusion, and speculation.

    "Whether that's good or bad is irrelevant," Fukuda said. "It's here, and public health must adapt."

    On other infectious disease topics, Frieden told the group that public health has had successes on some disease fronts, such as rapid pandemic H1N1 detection and pockets of progress with malaria prevention, but urged his colleagues to focus on basics such as patient-friendly treatments and supervision of healthcare workers' infection control practices.

    "The bottom line is there is no substitute for hard work," he said.

    Fauci emphasized the importance of continuing to battle infectious diseases, given their ability to reshape society. Emerging diseases such as HIV infection often become established, and sometimes established diseases such as tuberculosis (TB) can resurge in a more dangerous form, such as drug-resistant TB.

    "We have to use our knowledge to match the adaptive capabilities of microbes," he said.

    However, prevention still looms large, Fauci said, referring to promising new monoclonal antibody findings that might someday lead to an HIV vaccine.

    "We need to close the gap between seasonal influenza and pandemic influenza in our preparedness," he said. "We need to do what the CDC recommends?vaccinate everybody?and build better vaccine platforms."

    The ICEID, held every other year, is organized by the CDC, the Council of State and Territorial Epidemiologists, the Association of Public Health Laboratories, the WHO, and the American Society for Microbiology. Meeting organizers said they had about 1,600 registrants from about 88 countries.


  • #2
    Re: Cidrap: ICEID COVERAGE Experts air H1N1 lessons, other disease challenges

    ICEID COVERAGE
    Experts anticipate new flu-fighting tools


    Lisa Schnirring * Staff Writer

    Jul 13, 2010 ATLANTA (CIDRAP News) ? As the world recovers its bearings after spikes in pandemic flu activity and anticipates how the upcoming flu season will unfold, antiviral and vaccine experts in Atlanta today plotted out the new prevention and treatment tools public health officials may someday use to fine-tune their disease responses.

    The tools range from new antivirals undergoing testing in unique combinations through novel routes of administration to influenza vaccine proteins that are harvested from plants in greenhouse factories. Experts presented the new developments at the International Conference on Emerging Infectious Diseases (ICEID) in Atlanta.

    What's next for antivirals?
    Virologist Fred Hayden, MD, said neuraminidase inhibitors have traditionally played a prominent role in flu prophylaxis and treatment, but recent research findings from their use in severely hospitalized patients during the H1N1 pandemic have showed benefits, even when started late. However, he said researchers have noted prolonged virus replication in the lower respiratory tract in some seriously ill patients who have been prescribed the drugs, and still note some poor outcomes in patients who received the drugs early.

    "There's room for improvement for a more robust antiviral," said Hayden, a virologist at the University of Virginia and flu research coordinator for Wellcome Trust, a London-based nonprofit group.

    Three of the antivirals that are advancing through trials are neuraminidase inhibitors, the class to which the already-approved oseltamivir (Tamiflu) and zanamivir (Relenza) belong.

    Intravenous (IV) peramivir, which was used under an emergency use authorization in the United States, is in phase 3 trials and has already received regulatory approval in Japan, he said. During the H1N1 pandemic more than 500 courses of peramivir were used throughout the world, Hayden added.

    Clinical findings during the pandemic, however, have raised some doubts about its effectiveness in treating oseltamivir-resistant influenza, Hayden said. "IV zanamivir is still the treatment of choice if oseltamivir resistance is suspected or proven."

    Because neuraminidase inhibitors have different spectrums of activity, other new research avenues are exploring combination therapies, he said. For example, in vitro and animal studies on combination therapy using the new drug favipiravir have shown encouraging results, and the combination is on the verge of being studied in hospitalized patients.

    However, Hayden said some neuraminidase inhibitor combinations have shown additive antagonistic activity, and scientists should look at the variability in the data and look at the findings very carefully.

    One obstacle that could slow the delivery of new neuraminidase inhibitors to the marketplace is a lack of regulatory agreement on appropriate endpoints for hospitalized patients, not just clinical but also virological. "Dialogues are still in progress, and studies are under way to help guide this," Hayden said.

    Changing vaccine landscape
    Rick Bright, PhD, said about 75 new flu vaccine technologies are moving forward on several different fronts and in several different countries, including a handful of developing countries. The recent pandemic vaccine experience showed how poorly traditional flu vaccine production is equipped to respond to surge demands, as well as a lack of capacity that results to a 6-billion-dose gap for the global population, he said.

    Bright is scientific director for the influenza vaccine project at PATH (Program for Appropriate Technology in Health), a global nonprofit health group.

    He said the most promising flu vaccines on the horizon involve live attenuated influenza vaccine (LAIV), virus-like particle (VLP), plant-based, and universal flu vaccine technology, with each having its own set of strengths and challenges. Bright said, for example, that LAIV products are one of the lowest-cost vaccines to make and can be rapidly produced, but they face regulatory barriers in developing countries that might have difficulty evaluating them without large efficacy trials.

    VLP vaccines have a high yield and production technology can easily be transferred to developing countries, but companies will face additional regulatory hurdles as they demonstrate the safety of residual vectors that relate to production in, for example, insect cells or fungi, he said. Some of the VLP companies are newer and aren't as experienced at navigating the regulatory landscape or assembling product financing, Bright added.

    So far, VLP vaccines don't appear to be as immunogenic as other platforms, Bright said. He speculated that some of the benefits might be "purified away" during production. "Most would probably benefit greatly from an adjuvant," he said.

    Bright said plant-based flu vaccines have faced historical challenges, but have progressed quickly since 2000. He said vaccines using the method can be produced very rapidly, in 8 weeks, with very high yields. For example, he said a plant vaccine center at Texas A&M University expects to be able to produce 100 million doses per month.

    Regarding DNA-based vaccines, more work is needed to identify correlates of protection, Bright said. "We don't really know if they're effective," he said, adding that they might be useful as a supplement for hemagglutinin vaccines.

    New tools for developing countries
    W. Abdullah Brooks, MD, MPH, who works in Bangladesh with the Johns Hopkins Bloomberg School of Public Health, said the world's recent focus on the pandemic vaccine has raised new issues about possible new roles for flu vaccines in developing countries.

    Childhood pneumonia represents a big health burden in developing countries, and some health officials are eyeing influenza vaccines as a strategy for cutting deaths from pneumonia. Better surveillance in the countries could help define if flu viruses are contributing to severe pneumonia infections. He said countries are likely to have different objectives?controlling seasonal flu or reducing morbidity from pneumonia.

    Brooks suggested that one way forward for developing countries is to administer one flu vaccine dose to children between their first and second birthdays at the same time as measles vaccination. "That would get them to their second birthday and may also have some impact on secondary transmission," he said.

    Comment


    • #3
      Re: Cidrap: ICEID COVERAGE Experts air H1N1 lessons, other disease challenges

      ICEID COVERAGE
      Research continues on shielding workers from airborne pathogens


      Jul 14, 2010 ATLANTA (CIDRAP News) ? The early response to the H1N1 pandemic exposed ongoing sore points regarding protection of workers in healthcare and other settings during epidemics or bioterrorist attacks, and federal researchers today highlighted current efforts to address some of the concerns.

      They covered emerging issues such as a need for more surge capacity for airborne-pathogen isolation units and possible enhancements for guidance on responding to anthrax attacks in workplace settings. The experts presented their updates in a panel discussion at the International Conference on Emerging Infectious Diseases (ICEID).

      Kenneth Mead, PhD, a senior research engineer at the National Institute for Occupational Safety and Health (NIOSH) in Cincinnati, said the nation needs a way to quickly boost surge capacity for airborne isolation units such as negative-pressure rooms. In preparing his doctoral dissertation on the topic, he said he found that 40% of hospitals lack engineered airborne isolation rooms, which typically cost between $30,000 and $40,000 to construct.

      For example, the state of Nevada has said it has 307 airborne isolation unit beds for its population of 2.5 million, along with 4 million tourists who visit the state each month, he reported.

      Adequate protection of healthcare workers is a crucial issue in planning response to major public health events, Mead said. He referred to a study of healthcare workers in New York during the SARS (severe acute respiratory syndrome) episode that revealed that only 24% would report to work.

      Current airborne isolation units in hospitals are designed more to protect the hospital environment than the workers or the people being treated in the rooms, Mead said. The systems are based on dilution ventilation, which, because it is so slow to reduce harmful aerosols, doesn't provide a meaningful level of protection.

      Mead's dissertation led him to explore ways to cheaply and quickly surge airborne isolation areas in emergency settings. He said current options such as creating a big "hot zone" isolation area or simply transferring patients aren't always practical or worker-friendly.

      He explored two other possibilities: creating a "zone within a zone" that replaces the fabric curtain around a patient's hospital bed with plastic and installing a portable HEPA filter within the area, and a ventilated headboard that captures pathogens before they have the chance to disperse.

      Field studies at four hospitals showed both options were effective at reducing airborne pathogens, Mead said, and now NIOSH is developing prototypes that are inexpensive and portable for further testing.

      Meanwhile, Kenneth Martinez, PhD, a scientist with the Department of Defense, said the US Centers for Disease Control and Prevention (CDC) is supporting research to assess if current anthrax-control protocols in open office environments, such as those that contain cubicles, could be improved.

      In a simulated open office setting, scientists have conducted letter-opening simulation trials using spores of Bacillus atrophaeus, an anthrax surrogate, to gauge how quickly workers are exposed and to what extent, Martinez reported. They're exploring whether having the worker who opens the letter wait 5 minutes before leaving the building reduces exposure of other workers. He said so far the waiting period doesn't appear to make a difference.

      Scientists are also gauging exposure during emergency response for both the first responders and the letter opener, Martinez said. So far the group has found that spraying the worker with a corn oil substance is effective at preventing spores from re-aerosolizing.

      See also:

      ICEID home page
      CDC’s preeminent conference on emerging infectious diseases.


      Comment

      Working...
      X